Non-Small Cell Lung Cancer
Advertisement
Stephen V. Liu, MD, shares what he sees as the key upcoming highlights in thoracic oncology at the ASCO Annual Meeting.
Eric Singhi, MD, discusses the recent FDA approval and explains the associated new biomarker testing considerations.
Study Highlights Relationship Between Lipid Metabolism, NK Cells in the NSCLC Tumor Microenvironment
Study investigators suggested there may be a “promising therapeutic strategy for advancing NK cell-based immunotherapy."
The accelerated approval is specifically for patients with high c-Met protein overexpression.
The phase 2 platform study has been assessing the combination of belrestotug plus dostarlimab in NSCLC.
Researchers synthesized circular RNA encoding NY-ESO-1, which is expressed in a proportion of patients with NSCLC.
Dr. Spira shares key data from cohort C of CHRYSALIS-2 that was presented at the European Lung Cancer Congress 2025.
The study explored the effect of immune checkpoint inhibition on real-world patients with NSCLC versus trial patients.
The phase 1 LuCa-MERIT-1 trial is evaluating BNT116, an unmodified RNA-based lipoplex cancer vaccine, with cemiplimab.
Solange Peters, MD, PhD, presented results from the trial evaluating tiragolumab plus atezolizumab.
John V. Heymach, MD, PhD, of the MD Anderson Cancer Center, presented results from the trial at AACR 2025.
Kathryn C. Arbour, MD, of the Memorial Sloan Kettering Cancer Center, presented results from the study at AACR 2025.
Ivonescimab plus chemotherapy “demonstrated strongly positive results” as a first-line treatment for advanced squamous ...
Dr. Liu discusses key data and updates in EGFR-positive NSCLC from the European Lung Cancer Congress.
Dr. Shaw is being recognized for her "groundbreaking work in defining ALK- and ROS1-positive lung cancers," officials said.
A recent study may provide a "clearer, more individualized" understanding of progression risk after discontinuation.
Margarita Majem, MD, PhD, presented the results as a late-breaking abstract during the European Lung Cancer Congress 2025.
Nicolas Girard, MD, PhD, discusses data on subcutaneous amivantamab in patients with advanced NSCLC.
The session covered everything from new actionable immune checkpoints to vaccines, cellular therapies, and bispecifics.
Martin Reck, MD, PhD, reflects on key updates in stage III NSCLC from the European Lung Cancer Congress 2025.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.